Skip to main content
Erschienen in: Diabetologia 1/2003

01.01.2003 | Review

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

verfasst von: S. E. Kahn

Erschienen in: Diabetologia | Ausgabe 1/2003

Einloggen, um Zugang zu erhalten

Abstract

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes have been debated extensively. The concept that a feedback loop governs the interaction of the insulin-sensitive tissues and the beta cell as well as the elucidation of the hyperbolic relationship between insulin sensitivity and insulin secretion explains why insulin-resistant subjects exhibit markedly increased insulin responses while those who are insulin-sensitive have low responses. Consideration of this hyperbolic relationship has helped identify the critical role of beta-cell dysfunction in the development of Type 2 diabetes and the demonstration of reduced beta-cell function in high risk subjects. Furthermore, assessments in a number of ethnic groups emphasise that beta-cell function is a major determinant of oral glucose tolerance in subjects with normal and reduced glucose tolerance and that in all populations the progression from normal to impaired glucose tolerance and subsequently to Type 2 diabetes is associated with declining insulin sensitivity and beta-cell function. The genetic and molecular basis for these reductions in insulin sensitivity and beta-cell function are not fully understood but it does seem that body-fat distribution and especially intra-abdominal fat are major determinants of insulin resistance while reductions in beta-cell mass contribute to beta-cell dysfunction. Based on our greater understanding of the relative roles of insulin resistance and beta-cell dysfunction in Type 2 diabetes, we can anticipate advances in the identification of genes contributing to the development of the disease as well as approaches to the treatment and prevention of Type 2 diabetes.
Literatur
1.
Zurück zum Zitat Kahn SE, Porte D, Jr (1996) Pathophysiology of type II diabetes mellitus. In: Porte D Jr, Sherwin RS (eds) Diabetes mellitus. Appleton and Lange, Stamford, pp 487–512 Kahn SE, Porte D, Jr (1996) Pathophysiology of type II diabetes mellitus. In: Porte D Jr, Sherwin RS (eds) Diabetes mellitus. Appleton and Lange, Stamford, pp  487–512
2.
Zurück zum Zitat DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194PubMed DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194PubMed
3.
Zurück zum Zitat Kruszynska YT, Olefsky JM (1996) Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Investig Med 44:413–428PubMed Kruszynska YT, Olefsky JM (1996) Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Investig Med 44:413–428PubMed
4.
Zurück zum Zitat Porte D Jr (1991) β-cells in type II diabetes mellitus. Diabetes 40:166–180PubMed Porte D Jr (1991) β-cells in type II diabetes mellitus. Diabetes 40:166–180PubMed
5.
Zurück zum Zitat Mitrakou A, Kelley D, Mokan M et al. (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22–29PubMed Mitrakou A, Kelley D, Mokan M et al. (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22–29PubMed
6.
Zurück zum Zitat Kahn SE (2001) The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047–4058 Kahn SE (2001) The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047–4058
7.
Zurück zum Zitat National Heart Lung and Blood Institute (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Obes Res 6 [Suppl 2]:51S–209S National Heart Lung and Blood Institute (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Obes Res 6 [Suppl 2]:51S–209S
8.
Zurück zum Zitat King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMed King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMed
9.
Zurück zum Zitat Olefsky J, Farquhar JW, Reaven G (1973) Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes 22:507–513PubMed Olefsky J, Farquhar JW, Reaven G (1973) Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes 22:507–513PubMed
10.
Zurück zum Zitat Beard JC, Ward WK, Halter JB, Wallum BJ, Porte D Jr (1987) Relationship of islet function to insulin action in human obesity. J Clin Endocrinol Metab 65:59–64PubMed Beard JC, Ward WK, Halter JB, Wallum BJ, Porte D Jr (1987) Relationship of islet function to insulin action in human obesity. J Clin Endocrinol Metab 65:59–64PubMed
11.
Zurück zum Zitat Rosenbloom AL, Joe JR, Young RS, Winter WE (1999) Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22:345–354 Rosenbloom AL, Joe JR, Young RS, Winter WE (1999) Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22:345–354
12.
Zurück zum Zitat Dabelea D, Pettitt DJ, Jones KL, Arslanian SA (1999) Type 2 diabetes mellitus in minority children and adolescents. An emerging problem. Endocrinol Metab Clin North Am 28:709–729PubMed Dabelea D, Pettitt DJ, Jones KL, Arslanian SA (1999) Type 2 diabetes mellitus in minority children and adolescents. An emerging problem. Endocrinol Metab Clin North Am 28:709–729PubMed
13.
Zurück zum Zitat Sinha R, Fisch G, Teague B et al. (2002) Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346:802–810CrossRefPubMed Sinha R, Fisch G, Teague B et al. (2002) Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346:802–810CrossRefPubMed
14.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853PubMed UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853PubMed
15.
Zurück zum Zitat Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012PubMed Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012PubMed
16.
Zurück zum Zitat The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed
17.
Zurück zum Zitat Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (1998) UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15:297–303CrossRef Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (1998) UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15:297–303CrossRef
18.
Zurück zum Zitat Holman RR (1998) Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 40 [Suppl]:S21-S25 Holman RR (1998) Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 40 [Suppl]:S21-S25
19.
Zurück zum Zitat Virkamaki A, Ueki K, Kahn CR (1999) Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931–943PubMed Virkamaki A, Ueki K, Kahn CR (1999) Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931–943PubMed
20.
Zurück zum Zitat Barroso I, Gurnell M, Crowley VE et al. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880–883PubMed Barroso I, Gurnell M, Crowley VE et al. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880–883PubMed
21.
Zurück zum Zitat DeFronzo RA (1979) Glucose intolerance of aging. Evidence for tissue insensitivity to insulin. Diabetes 28:1095–1101PubMed DeFronzo RA (1979) Glucose intolerance of aging. Evidence for tissue insensitivity to insulin. Diabetes 28:1095–1101PubMed
22.
Zurück zum Zitat Chen M, Bergman RN, Pacini G, Porte D Jr (1985) Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased β-cell function. J Clin Endocrinol Metab 60:13–20PubMed Chen M, Bergman RN, Pacini G, Porte D Jr (1985) Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased β-cell function. J Clin Endocrinol Metab 60:13–20PubMed
23.
Zurück zum Zitat Prigeon RL, Kahn SE, Porte D Jr. (1995) Changes in insulin sensitivity, glucose effectiveness, and B-cell function in regularly exercising subjects. Metabolism 44:1259–1263PubMed Prigeon RL, Kahn SE, Porte D Jr. (1995) Changes in insulin sensitivity, glucose effectiveness, and B-cell function in regularly exercising subjects. Metabolism 44:1259–1263PubMed
24.
Zurück zum Zitat Kahn SE, Larson VG, Beard JC et al. (1990) Effect of exercise on insulin action, glucose tolerance and insulin secretion in aging. Am J Physiol 258:E937–E943PubMed Kahn SE, Larson VG, Beard JC et al. (1990) Effect of exercise on insulin action, glucose tolerance and insulin secretion in aging. Am J Physiol 258:E937–E943PubMed
25.
Zurück zum Zitat Chen M, Halter JB, Porte D Jr (1987) The role of dietary carbohydrate in the decreased glucose tolerance of the elderly. J Am Geriatr Soc 35:417–424PubMed Chen M, Halter JB, Porte D Jr (1987) The role of dietary carbohydrate in the decreased glucose tolerance of the elderly. J Am Geriatr Soc 35:417–424PubMed
26.
Zurück zum Zitat Beard JC, Halter JB, Best JD, Pfeifer MA, Porte D Jr (1984) Dexamethasone-induced insulin resistance enhances B-cell responsiveness to glucose level in normal men. Am J Physiol 247:E592–E596PubMed Beard JC, Halter JB, Best JD, Pfeifer MA, Porte D Jr (1984) Dexamethasone-induced insulin resistance enhances B-cell responsiveness to glucose level in normal men. Am J Physiol 247:E592–E596PubMed
27.
Zurück zum Zitat Rizza RA, Mandarino LJ, Gerich JE (1982) Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663–669PubMed Rizza RA, Mandarino LJ, Gerich JE (1982) Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663–669PubMed
28.
Zurück zum Zitat Kahn SE, Beard JC, Schwartz MW et al. (1989) Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562–568PubMed Kahn SE, Beard JC, Schwartz MW et al. (1989) Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562–568PubMed
29.
Zurück zum Zitat Kolterman OG, Insel J, Saekow M, Olefsky JM (1980) Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest 65:1272–1284PubMed Kolterman OG, Insel J, Saekow M, Olefsky JM (1980) Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest 65:1272–1284PubMed
30.
Zurück zum Zitat Lillioja S, Bogardus C (1988) Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 4:517–540PubMed Lillioja S, Bogardus C (1988) Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 4:517–540PubMed
31.
Zurück zum Zitat Bjorntorp P (1993) Visceral obesity: a "civilization syndrome". Obes Res 1:206–222 Bjorntorp P (1993) Visceral obesity: a "civilization syndrome". Obes Res 1:206–222
32.
Zurück zum Zitat Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH (1986) Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 78:1648–1657PubMed Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH (1986) Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 78:1648–1657PubMed
33.
Zurück zum Zitat Pouliot MC, Despres JP, Nadeau A et al. (1992) Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41:826–834PubMed Pouliot MC, Despres JP, Nadeau A et al. (1992) Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41:826–834PubMed
34.
Zurück zum Zitat Peiris AN, Sothmann MS, Hennes MI et al. (1989) Relative contribution of obesity and body fat distribution to alterations in glucose insulin homeostasis: predictive values of selected indices in premenopausal women. Am J Clin Nutr 49:758–764PubMed Peiris AN, Sothmann MS, Hennes MI et al. (1989) Relative contribution of obesity and body fat distribution to alterations in glucose insulin homeostasis: predictive values of selected indices in premenopausal women. Am J Clin Nutr 49:758–764PubMed
35.
Zurück zum Zitat Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD (1994) The visceral adiposity syndrome in Japanese-American men. Obes Res 2:364–371 Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD (1994) The visceral adiposity syndrome in Japanese-American men. Obes Res 2:364–371
36.
Zurück zum Zitat Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM (1995) Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 96:88–98PubMed Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM (1995) Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 96:88–98PubMed
37.
Zurück zum Zitat Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL (1999) Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 48:839–847PubMed Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL (1999) Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 48:839–847PubMed
38.
Zurück zum Zitat Cnop M, Landchild MJ, Vidal J et al. (2002) The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51:1005–1015PubMed Cnop M, Landchild MJ, Vidal J et al. (2002) The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51:1005–1015PubMed
39.
Zurück zum Zitat Taylor SI, Cama A, Accili D et al. (1992) Mutations in the insulin receptor gene. Endocr Rev 13:566–595PubMed Taylor SI, Cama A, Accili D et al. (1992) Mutations in the insulin receptor gene. Endocr Rev 13:566–595PubMed
40.
Zurück zum Zitat Xia J, Scherer SW, Cohen PT et al. (1998) A common variant in PPP1R3 associated with insulin resistance and type 2 diabetes. Diabetes 47:1519–1524PubMed Xia J, Scherer SW, Cohen PT et al. (1998) A common variant in PPP1R3 associated with insulin resistance and type 2 diabetes. Diabetes 47:1519–1524PubMed
41.
Zurück zum Zitat Hegele RA, Harris SB, Zinman B et al. (1998) Variation in the AU(AT)-rich element within the 3′-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians. J Clin Endocrinol Metab 83:3980–3983PubMed Hegele RA, Harris SB, Zinman B et al. (1998) Variation in the AU(AT)-rich element within the 3′-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians. J Clin Endocrinol Metab 83:3980–3983PubMed
42.
Zurück zum Zitat Hansen L, Hansen T, Vestergaard H et al. (1995) A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hum Mol Genet 4:1313–1320PubMed Hansen L, Hansen T, Vestergaard H et al. (1995) A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hum Mol Genet 4:1313–1320PubMed
43.
Zurück zum Zitat Hansen L, Reneland R, Berglund L et al. (2000) Polymorphism in the glycogen-associated regulatory subunit of type 1 protein phosphatase (PPP1R3) gene and insulin sensitivity. Diabetes 49:298–301PubMed Hansen L, Reneland R, Berglund L et al. (2000) Polymorphism in the glycogen-associated regulatory subunit of type 1 protein phosphatase (PPP1R3) gene and insulin sensitivity. Diabetes 49:298–301PubMed
44.
Zurück zum Zitat Stumvoll M, Tschritter O, Fritsche A et al. (2002) Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 51:37–41PubMed Stumvoll M, Tschritter O, Fritsche A et al. (2002) Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 51:37–41PubMed
45.
Zurück zum Zitat Hasstedt SJ, Ren QF, Teng K, Elbein SC (2001) Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 86:536–541PubMed Hasstedt SJ, Ren QF, Teng K, Elbein SC (2001) Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 86:536–541PubMed
46.
Zurück zum Zitat Deeb SS, Fajas L, Nemoto M et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287 Deeb SS, Fajas L, Nemoto M et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287
47.
Zurück zum Zitat Altshuler D, Hirschhorn JN, Klannemark M et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMed Altshuler D, Hirschhorn JN, Klannemark M et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMed
48.
Zurück zum Zitat Horton ES (1986) Exercise and physical training: effects on insulin sensitivity and glucose metabolism. Diabetes Metab Rev 2:1–17PubMed Horton ES (1986) Exercise and physical training: effects on insulin sensitivity and glucose metabolism. Diabetes Metab Rev 2:1–17PubMed
49.
Zurück zum Zitat Chen M, Bergman RN, Porte D Jr (1988) Insulin resistance and β-cell dysfunction in aging: the importance of dietary carbohydrate. J Clin Endocrinol Metab 67:951–957PubMed Chen M, Bergman RN, Porte D Jr (1988) Insulin resistance and β-cell dysfunction in aging: the importance of dietary carbohydrate. J Clin Endocrinol Metab 67:951–957PubMed
50.
Zurück zum Zitat Brunzell JD, Lerner RL, Hazzard WR, Porte D Jr, Bierman EL (1971) Improved glucose tolerance with high carbohydrate feeding in mild diabetes. N Engl J Med 284:521–524PubMed Brunzell JD, Lerner RL, Hazzard WR, Porte D Jr, Bierman EL (1971) Improved glucose tolerance with high carbohydrate feeding in mild diabetes. N Engl J Med 284:521–524PubMed
51.
Zurück zum Zitat Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C (1990) Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10:497–511PubMed Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C (1990) Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10:497–511PubMed
52.
Zurück zum Zitat Peiris AN, Sothmann MS, Hoffmann RG et al. (1989) Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 110:867–872PubMed Peiris AN, Sothmann MS, Hoffmann RG et al. (1989) Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 110:867–872PubMed
53.
Zurück zum Zitat Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM (1996) Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 45:1684–1693PubMed Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM (1996) Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 45:1684–1693PubMed
54.
Zurück zum Zitat Kahn SE, Prigeon RL, McCulloch DK et al. (1993) Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672PubMed Kahn SE, Prigeon RL, McCulloch DK et al. (1993) Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672PubMed
55.
Zurück zum Zitat Cnop M, Havel PJ, Utzschneider KM et al. (2002) Gender-based differences in adiponectin and leptin levels are related to differences in body fat distribution. Diabetes 50 [Suppl 2]:A404 (Abstract) Cnop M, Havel PJ, Utzschneider KM et al. (2002) Gender-based differences in adiponectin and leptin levels are related to differences in body fat distribution. Diabetes 50 [Suppl 2]:A404 (Abstract)
56.
Zurück zum Zitat Matsuzawa Y, Funahashi T, Nakamura T (1999) Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892:146–154PubMed Matsuzawa Y, Funahashi T, Nakamura T (1999) Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892:146–154PubMed
57.
Zurück zum Zitat Weyer C, Funahashi T, Tanaka S et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935 Weyer C, Funahashi T, Tanaka S et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935
58.
Zurück zum Zitat Hotta K, Funahashi T, Arita Y et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599 Hotta K, Funahashi T, Arita Y et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599
59.
Zurück zum Zitat Couillard C, Mauriege P, Prud'homme D et al. (1997) Plasma leptin concentrations: gender differences and associations with metabolic risk factors for cardiovascular disease. Diabetologia 40:1178–1184CrossRefPubMed Couillard C, Mauriege P, Prud'homme D et al. (1997) Plasma leptin concentrations: gender differences and associations with metabolic risk factors for cardiovascular disease. Diabetologia 40:1178–1184CrossRefPubMed
60.
Zurück zum Zitat Schwartz RS, Shuman WP, Bradbury VL et al. (1990) Body fat distribution in healthy young and older men. J Gerontol 45:M181-M185PubMed Schwartz RS, Shuman WP, Bradbury VL et al. (1990) Body fat distribution in healthy young and older men. J Gerontol 45:M181-M185PubMed
61.
Zurück zum Zitat Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS (2000) Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 85:977–982PubMed Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS (2000) Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 85:977–982PubMed
62.
Zurück zum Zitat Schwartz RS, Shuman WP, Larson V et al. (1991) The effect of intensive endurance exercise training on body fat distribution in young and older men. Metabolism 40:545–551PubMed Schwartz RS, Shuman WP, Larson V et al. (1991) The effect of intensive endurance exercise training on body fat distribution in young and older men. Metabolism 40:545–551PubMed
63.
64.
Zurück zum Zitat Hirose H, Kawai T, Yamamoto Y et al. (2002) Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51:314–317PubMed Hirose H, Kawai T, Yamamoto Y et al. (2002) Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51:314–317PubMed
65.
Zurück zum Zitat Mori Y, Murakawa Y, Okada K et al. (1999) Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908–912 Mori Y, Murakawa Y, Okada K et al. (1999) Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908–912
66.
Zurück zum Zitat Steppan CM, Bailey ST, Bhat S et al. (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312CrossRefPubMed Steppan CM, Bailey ST, Bhat S et al. (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312CrossRefPubMed
67.
Zurück zum Zitat Yang WS, Jeng CY, Wu TJ et al. (2002) Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376–380PubMed Yang WS, Jeng CY, Wu TJ et al. (2002) Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376–380PubMed
68.
Zurück zum Zitat Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46:1954–1962PubMed Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46:1954–1962PubMed
69.
Zurück zum Zitat Bagdade JD, Bierman EL, Porte D Jr (1967) The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 46:1549–1557PubMed Bagdade JD, Bierman EL, Porte D Jr (1967) The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 46:1549–1557PubMed
70.
Zurück zum Zitat Brunzell JD, Robertson RP, Lerner RL et al. (1976) Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42:222–229PubMed Brunzell JD, Robertson RP, Lerner RL et al. (1976) Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42:222–229PubMed
71.
Zurück zum Zitat Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr (1984) Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318–1328PubMed Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr (1984) Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318–1328PubMed
72.
Zurück zum Zitat Halter JB, Porte D Jr (1978) Mechanisms of impaired acute insulin release in adult onset diabetes: studies with isoproterenol and secretin. J Clin Endocrinol Metab 46:952–960PubMed Halter JB, Porte D Jr (1978) Mechanisms of impaired acute insulin release in adult onset diabetes: studies with isoproterenol and secretin. J Clin Endocrinol Metab 46:952–960PubMed
73.
Zurück zum Zitat Varsano-Aharon N, Echemendia E, Yalow RS, Berson SA (1970) Early insulin responses to glucose and to tolbutamide in maturity-onset diabetes. Metabolism 19:409–417PubMed Varsano-Aharon N, Echemendia E, Yalow RS, Berson SA (1970) Early insulin responses to glucose and to tolbutamide in maturity-onset diabetes. Metabolism 19:409–417PubMed
74.
Zurück zum Zitat O'Rahilly S, Turner RC, Matthews DR (1988) Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 318:1225–1230PubMed O'Rahilly S, Turner RC, Matthews DR (1988) Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 318:1225–1230PubMed
75.
Zurück zum Zitat Porksen N (2002) The in vivo regulation of pulsatile insulin secretion. Diabetologia 45:3–20PubMed Porksen N (2002) The in vivo regulation of pulsatile insulin secretion. Diabetologia 45:3–20PubMed
76.
Zurück zum Zitat Polonsky KS, Given BD, Hirsch LJ et al. (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231–1239PubMed Polonsky KS, Given BD, Hirsch LJ et al. (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231–1239PubMed
77.
Zurück zum Zitat Mako ME, Starr JI, Rubenstein AH (1977) Circulating proinsulin in patients with maturity-onset diabetes. Am J Med 63:865–869PubMed Mako ME, Starr JI, Rubenstein AH (1977) Circulating proinsulin in patients with maturity-onset diabetes. Am J Med 63:865–869PubMed
78.
Zurück zum Zitat Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr (1987) Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and experimental insulin resistance. Diabetologia 30:698–702PubMed Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr (1987) Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and experimental insulin resistance. Diabetologia 30:698–702PubMed
79.
Zurück zum Zitat Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y (1988) Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31:355–360PubMed Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y (1988) Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31:355–360PubMed
80.
Zurück zum Zitat Temple RC, Clark PM, Nagi DK, Schneider AE, Yudkin JS, Hales CN (1990) Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol (Oxf) 32:689–693 Temple RC, Clark PM, Nagi DK, Schneider AE, Yudkin JS, Hales CN (1990) Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol (Oxf) 32:689–693
81.
Zurück zum Zitat Saad MF, Kahn SE, Nelson RG et al. (1990) Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 70:1247–1253PubMed Saad MF, Kahn SE, Nelson RG et al. (1990) Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 70:1247–1253PubMed
82.
Zurück zum Zitat Kahn SE, Leonetti DL, Prigeon RL, Bergstrom RW, Fujimoto WY (1995) Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese American men: impact of obesity. J Clin Endocrinol Metab 80:1399–1406PubMed Kahn SE, Leonetti DL, Prigeon RL, Bergstrom RW, Fujimoto WY (1995) Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese American men: impact of obesity. J Clin Endocrinol Metab 80:1399–1406PubMed
83.
Zurück zum Zitat Kahn SE, Halban PA (1997) Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725–1732PubMed Kahn SE, Halban PA (1997) Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725–1732PubMed
84.
Zurück zum Zitat Sanke T, Hanabusa T, Nakano Y et al. (1991) Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:129–132PubMed Sanke T, Hanabusa T, Nakano Y et al. (1991) Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:129–132PubMed
85.
Zurück zum Zitat Ludvik B, Lell B, Hartter E, Schnack C, Prager R (1991) Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 40:1615–1619PubMed Ludvik B, Lell B, Hartter E, Schnack C, Prager R (1991) Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 40:1615–1619PubMed
86.
Zurück zum Zitat Enoki S, Mitsukawa T, Takemura J et al. (1992) Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15:97–102PubMed Enoki S, Mitsukawa T, Takemura J et al. (1992) Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15:97–102PubMed
87.
Zurück zum Zitat Kahn SE, Verchere CB, Andrikopoulos S et al. (1998) Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47:640–645PubMed Kahn SE, Verchere CB, Andrikopoulos S et al. (1998) Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47:640–645PubMed
88.
Zurück zum Zitat Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group (2002) β-cell function is the major determinant of oral glucose tolerance in four ethnic groups in the United States. Diabetes 51:2170–2178PubMed Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group (2002) β-cell function is the major determinant of oral glucose tolerance in four ethnic groups in the United States. Diabetes 51:2170–2178PubMed
89.
Zurück zum Zitat Yalow RS, Berson SA (1960) Plasma insulin concentrations in nondiabetic and early diabetic subjects: determinations by a new sensitive immunoassay technic. Diabetes 9:254–260 Yalow RS, Berson SA (1960) Plasma insulin concentrations in nondiabetic and early diabetic subjects: determinations by a new sensitive immunoassay technic. Diabetes 9:254–260
90.
Zurück zum Zitat Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr (1984) Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7:491–502PubMed Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr (1984) Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7:491–502PubMed
91.
Zurück zum Zitat Karam JH, Grodsky GM, Forsham PH (1963) Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 12:197–204 Karam JH, Grodsky GM, Forsham PH (1963) Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 12:197–204
92.
Zurück zum Zitat Bagdade JD, Porte D Jr, Brunzell JD, Bierman EL (1974) Basal and stimulated hyperinsulinism: reversible metabolic sequelae of obesity. J Lab Clin Med 83:563–569PubMed Bagdade JD, Porte D Jr, Brunzell JD, Bierman EL (1974) Basal and stimulated hyperinsulinism: reversible metabolic sequelae of obesity. J Lab Clin Med 83:563–569PubMed
93.
Zurück zum Zitat Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMed Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMed
94.
Zurück zum Zitat Clausen JO, Borch-Johnsen K, Ibsen H et al. (1996) Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. J Clin Invest 98:1195–1209 Clausen JO, Borch-Johnsen K, Ibsen H et al. (1996) Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. J Clin Invest 98:1195–1209
95.
Zurück zum Zitat Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794 Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794
96.
Zurück zum Zitat Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS (1995) Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 96:520–527PubMed Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS (1995) Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 96:520–527PubMed
97.
Zurück zum Zitat Kahn SE (1996) Regulation of B-cell function in vivo: from health to disease. Diabetes Rev 4:372–389 Kahn SE (1996) Regulation of B-cell function in vivo: from health to disease. Diabetes Rev 4:372–389
98.
Zurück zum Zitat Elbein SC, Wegner K, Kahn SE (2000) Reduced β-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care 23:221–227PubMed Elbein SC, Wegner K, Kahn SE (2000) Reduced β-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care 23:221–227PubMed
99.
Zurück zum Zitat Ward WK, Johnston CLW, Beard JC, Benedetti TJ, Halter JB, Porte D Jr (1985) Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 34:861–869PubMed Ward WK, Johnston CLW, Beard JC, Benedetti TJ, Halter JB, Porte D Jr (1985) Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 34:861–869PubMed
100.
Zurück zum Zitat Ryan EA, Imes S, Liu D et al. (1995) Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes 44:506–512PubMed Ryan EA, Imes S, Liu D et al. (1995) Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes 44:506–512PubMed
101.
Zurück zum Zitat Buchanan TA, Xiang AH, Kjos SL, Trigo E, Lee WP, Peters RK (1999) Antepartum predictors of the development of type 2 diabetes in Latino women 11–26 months after pregnancies complicated by gestational diabetes. Diabetes 48:2430–2436PubMed Buchanan TA, Xiang AH, Kjos SL, Trigo E, Lee WP, Peters RK (1999) Antepartum predictors of the development of type 2 diabetes in Latino women 11–26 months after pregnancies complicated by gestational diabetes. Diabetes 48:2430–2436PubMed
102.
Zurück zum Zitat Dunaif A, Finegood DT (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:942–947PubMed Dunaif A, Finegood DT (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:942–947PubMed
103.
Zurück zum Zitat Kahn SE, Larson VG, Schwartz RS et al. (1992) Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging. J Clin Endocrinol Metab 74:1336–1342PubMed Kahn SE, Larson VG, Schwartz RS et al. (1992) Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging. J Clin Endocrinol Metab 74:1336–1342PubMed
104.
Zurück zum Zitat Larsson H, Ahren B (1996) Islet dysfunction in obese women with impaired glucose tolerance. Metabolism 45:502–509PubMed Larsson H, Ahren B (1996) Islet dysfunction in obese women with impaired glucose tolerance. Metabolism 45:502–509PubMed
105.
Zurück zum Zitat Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS (1997) Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530–537PubMed Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS (1997) Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530–537PubMed
106.
Zurück zum Zitat Knowles NG, Landchild MA, Fujimoto WY, Kahn SE (2002) Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 25:292–297PubMed Knowles NG, Landchild MA, Fujimoto WY, Kahn SE (2002) Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 25:292–297PubMed
107.
Zurück zum Zitat Elbein SC, Hasstedt SJ, Wegner K, Kahn SE (1999) Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 84:1398–1403PubMed Elbein SC, Hasstedt SJ, Wegner K, Kahn SE (1999) Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 84:1398–1403PubMed
108.
Zurück zum Zitat Haffner S, Stern M, Hazuda H, Mitchell B, Patterson J (1988) Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med 319:1297–1301 Haffner S, Stern M, Hazuda H, Mitchell B, Patterson J (1988) Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med 319:1297–1301
109.
Zurück zum Zitat Lillioja S, Mott DM, Howard BV et al. (1988) Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217–1225PubMed Lillioja S, Mott DM, Howard BV et al. (1988) Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217–1225PubMed
110.
Zurück zum Zitat Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR (1990) Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909–915PubMed Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR (1990) Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909–915PubMed
111.
Zurück zum Zitat Martin BL, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925–929PubMed Martin BL, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925–929PubMed
112.
Zurück zum Zitat Eriksson J, Franssila Kallunki A, Ekstrand A et al. (1989) Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337–343PubMed Eriksson J, Franssila Kallunki A, Ekstrand A et al. (1989) Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337–343PubMed
113.
Zurück zum Zitat Lillioja S, Mott DM, Spraul M et al. (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988–1992PubMed Lillioja S, Mott DM, Spraul M et al. (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988–1992PubMed
114.
Zurück zum Zitat Ferrannini E (1998) Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 19:477–490PubMed Ferrannini E (1998) Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 19:477–490PubMed
115.
Zurück zum Zitat Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P (1989) Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32:240–244PubMed Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P (1989) Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32:240–244PubMed
116.
Zurück zum Zitat Kahn SE, D'Alessio DA, Schwartz MW et al. (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634–638PubMed Kahn SE, D'Alessio DA, Schwartz MW et al. (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634–638PubMed
117.
Zurück zum Zitat Kahn SE, Fujimoto WY, D'Alessio DA, Ensinck JW, Porte D Jr (1991) Glucose stimulates and potentiates islet amyloid polypeptide secretion by the B-cell. Horm Metab Res 23:577–580PubMed Kahn SE, Fujimoto WY, D'Alessio DA, Ensinck JW, Porte D Jr (1991) Glucose stimulates and potentiates islet amyloid polypeptide secretion by the B-cell. Horm Metab Res 23:577–580PubMed
118.
Zurück zum Zitat Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE (1998) Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol 275:E785–E791PubMed Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE (1998) Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol 275:E785–E791PubMed
119.
Zurück zum Zitat Larsson H, Ahren B (1995) Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. Pancreas 11:201–205PubMed Larsson H, Ahren B (1995) Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. Pancreas 11:201–205PubMed
120.
Zurück zum Zitat Landchild MJ, Knowles NG, Yao Q et al. (2000) Increased β-cell secretory demand is not the simple explanation for inefficient proinsulin processing and islet amyloid formation in type 2 diabetes. J Investig Med 48:21A (Abstract) Landchild MJ, Knowles NG, Yao Q et al. (2000) Increased β-cell secretory demand is not the simple explanation for inefficient proinsulin processing and islet amyloid formation in type 2 diabetes. J Investig Med 48:21A (Abstract)
121.
Zurück zum Zitat Pimenta W, Korytkowski M, Mitrakou A et al. (1995) Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273:1855–1861 Pimenta W, Korytkowski M, Mitrakou A et al. (1995) Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273:1855–1861
122.
Zurück zum Zitat Schmitz O, Porksen N, Nyholm B et al. (1997) Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol 272:E218–E226PubMed Schmitz O, Porksen N, Nyholm B et al. (1997) Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol 272:E218–E226PubMed
123.
Zurück zum Zitat Larsson H, Ahren B (1996) Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 39:1099–1107CrossRefPubMed Larsson H, Ahren B (1996) Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 39:1099–1107CrossRefPubMed
124.
Zurück zum Zitat O'Meara NM, Sturis J, Van Cauter E, Polonsky KS (1993) Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest 92:262–271PubMed O'Meara NM, Sturis J, Van Cauter E, Polonsky KS (1993) Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest 92:262–271PubMed
125.
Zurück zum Zitat Phillips DI, Clark PM, Hales CN, Osmond C (1994) Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286–292PubMed Phillips DI, Clark PM, Hales CN, Osmond C (1994) Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286–292PubMed
126.
Zurück zum Zitat Kelley D, Mokan M, Veneman T (1994) Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus. Metabolism 43:1549–1557PubMed Kelley D, Mokan M, Veneman T (1994) Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus. Metabolism 43:1549–1557PubMed
127.
Zurück zum Zitat American Diabetes Association (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197PubMed American Diabetes Association (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197PubMed
128.
Zurück zum Zitat Clark A, Saad MF, Nezzer T et al. (1990) Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285–289PubMed Clark A, Saad MF, Nezzer T et al. (1990) Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285–289PubMed
129.
Zurück zum Zitat Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241–253PubMed Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241–253PubMed
130.
Zurück zum Zitat Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets. Proc Natl Acad Sci USA 84:3881–3885PubMed Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets. Proc Natl Acad Sci USA 84:3881–3885PubMed
131.
Zurück zum Zitat Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628–8632PubMed Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628–8632PubMed
132.
Zurück zum Zitat Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036–5040PubMed Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036–5040PubMed
133.
Zurück zum Zitat Verchere CB, D'Alessio DA, Palmiter RD et al. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492–3496CrossRefPubMed Verchere CB, D'Alessio DA, Palmiter RD et al. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492–3496CrossRefPubMed
134.
Zurück zum Zitat Soeller WC, Janson J, Hart SE et al. (1998) Islet amyloid-associated diabetes in obese Avy/a mice expressing human islet amyloid polypeptide. Diabetes 47:743–750PubMed Soeller WC, Janson J, Hart SE et al. (1998) Islet amyloid-associated diabetes in obese Avy/a mice expressing human islet amyloid polypeptide. Diabetes 47:743–750PubMed
135.
Zurück zum Zitat Höppener JW, Oosterwijk C, Nieuwenhuis MG et al. (1999) Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42:427–434CrossRefPubMed Höppener JW, Oosterwijk C, Nieuwenhuis MG et al. (1999) Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42:427–434CrossRefPubMed
136.
Zurück zum Zitat Howard CF Jr (1986) Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29:301–306PubMed Howard CF Jr (1986) Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29:301–306PubMed
137.
Zurück zum Zitat Wang F, Hull RL, Vidal J, Cnop M, Kahn SE (2001) Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514–2520PubMed Wang F, Hull RL, Vidal J, Cnop M, Kahn SE (2001) Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514–2520PubMed
138.
Zurück zum Zitat Yki-Järvinen H (1992) Glucose toxicity. Endocr Rev 13:415–431PubMed Yki-Järvinen H (1992) Glucose toxicity. Endocr Rev 13:415–431PubMed
139.
Zurück zum Zitat Robertson RP, Olson LK, Zhang HJ (1994) Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 43:1085–1089PubMed Robertson RP, Olson LK, Zhang HJ (1994) Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 43:1085–1089PubMed
140.
Zurück zum Zitat Garvey WT, Olefsky JM, Griffen J, Hamman RF, Kolterman OG (1985) The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222–234PubMed Garvey WT, Olefsky JM, Griffen J, Hamman RF, Kolterman OG (1985) The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222–234PubMed
141.
Zurück zum Zitat Kahn SE, Bergman RN, Schwartz MW, Taborsky GJ Jr, Porte D Jr (1992) Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. Am J Physiol 262:E518–E523PubMed Kahn SE, Bergman RN, Schwartz MW, Taborsky GJ Jr, Porte D Jr (1992) Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. Am J Physiol 262:E518–E523PubMed
142.
Zurück zum Zitat Ward WK, Halter JB, Beard JC, Porte D Jr (1984) Adaptation of B and A cell function during prolonged glucose infusion in human subjects. Am J Physiol 246:E405–E411PubMed Ward WK, Halter JB, Beard JC, Porte D Jr (1984) Adaptation of B and A cell function during prolonged glucose infusion in human subjects. Am J Physiol 246:E405–E411PubMed
143.
Zurück zum Zitat Byrne MM, Sturis J, Polonsky KS (1995) Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol 268:E21–E27PubMed Byrne MM, Sturis J, Polonsky KS (1995) Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol 268:E21–E27PubMed
144.
Zurück zum Zitat Hartling SG, Røder ME, Dinesen B, Binder C (1996) Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp. Eur J Endocrinol 134:197–200PubMed Hartling SG, Røder ME, Dinesen B, Binder C (1996) Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp. Eur J Endocrinol 134:197–200PubMed
145.
Zurück zum Zitat Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD (1988) Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37:1020–1024PubMed Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD (1988) Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37:1020–1024PubMed
146.
Zurück zum Zitat Thompson AL, Lim-Fraser MY, Kraegen EW, Cooney GJ (2000) Effects of individual fatty acids on glucose uptake and glycogen synthesis in soleus muscle in vitro. Am J Physiol Endocrinol Metab 279:E577-E584PubMed Thompson AL, Lim-Fraser MY, Kraegen EW, Cooney GJ (2000) Effects of individual fatty acids on glucose uptake and glycogen synthesis in soleus muscle in vitro. Am J Physiol Endocrinol Metab 279:E577-E584PubMed
147.
Zurück zum Zitat Zhou YP, Grill VE (1994) Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93:870–876PubMed Zhou YP, Grill VE (1994) Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93:870–876PubMed
148.
Zurück zum Zitat Zhou YP, Grill V (1995) Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 80:1584–1590 Zhou YP, Grill V (1995) Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 80:1584–1590
149.
Zurück zum Zitat Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3–10PubMed Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3–10PubMed
150.
Zurück zum Zitat Roden M, Price TB, Perseghin G et al. (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859–2865PubMed Roden M, Price TB, Perseghin G et al. (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859–2865PubMed
151.
Zurück zum Zitat Griffin ME, Marcucci MJ, Cline GW et al. (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270–1274PubMed Griffin ME, Marcucci MJ, Cline GW et al. (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270–1274PubMed
152.
Zurück zum Zitat Boden G, Chen X, Rosner J, Barton M (1995) Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44:1239–1242PubMed Boden G, Chen X, Rosner J, Barton M (1995) Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44:1239–1242PubMed
153.
Zurück zum Zitat Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF (1999) Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 276:E1055–E1066PubMed Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF (1999) Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 276:E1055–E1066PubMed
154.
Zurück zum Zitat Paolisso G, Gambardella A, Amato L et al. (1995) Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 38:1295–1299PubMed Paolisso G, Gambardella A, Amato L et al. (1995) Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 38:1295–1299PubMed
155.
Zurück zum Zitat Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661–671PubMed Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661–671PubMed
156.
Zurück zum Zitat Porte D Jr, Seeley RJ, Woods SC, Baskin DG, Figlewicz DP, Schwartz MW (1998) Obesity, diabetes and the central nervous system. Diabetologia 41:863–881CrossRefPubMed Porte D Jr, Seeley RJ, Woods SC, Baskin DG, Figlewicz DP, Schwartz MW (1998) Obesity, diabetes and the central nervous system. Diabetologia 41:863–881CrossRefPubMed
157.
Zurück zum Zitat Eriksson K-F, Lindgarde F (1991) Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo: feasibility study. Diabetologia 34:891–898PubMed Eriksson K-F, Lindgarde F (1991) Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo: feasibility study. Diabetologia 34:891–898PubMed
158.
Zurück zum Zitat Pan XR, Li GW, Hu YH et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544PubMed Pan XR, Li GW, Hu YH et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544PubMed
159.
Zurück zum Zitat Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed
160.
Zurück zum Zitat Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077CrossRef Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077CrossRef
161.
Zurück zum Zitat Buchanan TA, Xiang AH, Peters RK et al. (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high- risk hispanic women. Diabetes 51:2796–2803PubMed Buchanan TA, Xiang AH, Peters RK et al. (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high- risk hispanic women. Diabetes 51:2796–2803PubMed
162.
Zurück zum Zitat The Diabetes Prevention Program Research Group (1999) The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623–634PubMed The Diabetes Prevention Program Research Group (1999) The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623–634PubMed
163.
Zurück zum Zitat Yusuf S, Gerstein H, Hoogwerf B et al. (2001) Ramipril and the development of diabetes. JAMA 286:1882–1885PubMed Yusuf S, Gerstein H, Hoogwerf B et al. (2001) Ramipril and the development of diabetes. JAMA 286:1882–1885PubMed
164.
Zurück zum Zitat Haffner S, Holman R, Califf R, McMurray J, Pehcer E (2002) Targeting post-prandial hyperglycemia to prevent type 2 diabetes: Rationale and design of the NAVIGATOR trial. Diabetologia 45 [Suppl 2]:A106 (Abstract) Haffner S, Holman R, Califf R, McMurray J, Pehcer E (2002) Targeting post-prandial hyperglycemia to prevent type 2 diabetes: Rationale and design of the NAVIGATOR trial. Diabetologia 45 [Suppl 2]:A106 (Abstract)
165.
Zurück zum Zitat Freeman DJ, Norrie J, Sattar N et al. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357–362 Freeman DJ, Norrie J, Sattar N et al. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357–362
166.
Zurück zum Zitat Welch S, Gebhart SSP, Bergman RN, Phillips LS (1990) Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508–1518PubMed Welch S, Gebhart SSP, Bergman RN, Phillips LS (1990) Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508–1518PubMed
167.
Zurück zum Zitat Vidal J, Kahn SE (2001) Regulation of insulin secretion in vivo. In: Lowe WL Jr (ed.) Genetics of Diabetes Mellitus. Kluwer, Stamford, pp 109–131 Vidal J, Kahn SE (2001) Regulation of insulin secretion in vivo. In: Lowe WL Jr (ed.) Genetics of Diabetes Mellitus. Kluwer, Stamford, pp 109–131
Metadaten
Titel
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes
verfasst von
S. E. Kahn
Publikationsdatum
01.01.2003
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 1/2003
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-002-1009-0

Weitere Artikel der Ausgabe 1/2003

Diabetologia 1/2003 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.